FDA Notification Regarding Dehydrated Alcohol

Why It Matters

Unapproved dehydrated alcohol poses safety and compliance risks, and its removal protects patients while reinforcing FDA’s drug‑approval authority. Companies that ignore the notice face enforcement actions, including product seizure and civil penalties.

Key Takeaways

• Only Belcher's Ablysinol (NDC 62250‑105) is FDA‑approved for dehydrated alcohol
• Eight other NDCs listed are unapproved new drugs
• FDA requires a new drug application before interstate distribution
• Manufacturers risk enforcement actions if they continue selling unapproved products

Pulse Analysis

The FDA’s June 21, 2018 approval of Belcher Pharmaceuticals’ Ablysinol marked the first and only sanctioned dehydrated alcohol product in the United States. Approved in 1 mL and 5 mL ampules, Ablysinol is used primarily for intra‑arterial infusion during cardiac surgery, where its rapid vasodilatory effect can be life‑saving. The narrow approval underscores the agency’s cautious stance on this niche therapeutic class, reflecting both the drug’s potential benefits and the need for rigorous safety data.

Despite the singular approval, several manufacturers have marketed dehydrated alcohol under different NDC codes, bypassing the new‑drug application process. These unapproved products lack FDA‑reviewed efficacy and safety data, exposing patients to unknown risks such as contamination, dosing errors, or adverse reactions. The FDA’s recent notification serves as a pre‑emptive enforcement measure, reminding firms that interstate commerce of unapproved drugs violates the Federal Food, Drug, and Cosmetic Act and can trigger product seizures, injunctions, and civil monetary penalties.

The agency also highlights the NDC Directory as a transparent tool for verifying a drug’s approval status. Companies with unapproved dehydrated alcohol are encouraged to file new drug applications, which involve comprehensive clinical, manufacturing, and labeling reviews. By aligning with FDA pathways, firms can secure market access while safeguarding public health. For investors and stakeholders, the crackdown signals heightened regulatory scrutiny in niche drug categories, reinforcing the importance of compliance and the value of approved, evidence‑based therapeutics.